Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $86.3 million.

  • Ocular Therapeutix's Non-cash Items rose 10750.78% to $86.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $86.3 million, marking a year-over-year increase of 10750.78%. This contributed to the annual value of $86.3 million for FY2025, which is 65538.56% up from last year.
  • Per Ocular Therapeutix's latest filing, its Non-cash Items stood at $86.3 million for Q4 2025, which was up 10750.78% from $41.6 million recorded in Q4 2024.
  • In the past 5 years, Ocular Therapeutix's Non-cash Items ranged from a high of $86.3 million in Q4 2025 and a low of $7000.0 during Q4 2022
  • Its 5-year average for Non-cash Items is $28.9 million, with a median of $13.3 million in 2021.
  • In the last 5 years, Ocular Therapeutix's Non-cash Items plummeted by 9994.73% in 2022 and then soared by 4795714.29% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Non-cash Items (Quarter) stood at $13.3 million in 2021, then crashed by 99.95% to $7000.0 in 2022, then soared by 47957.14% to $3.4 million in 2023, then soared by 1135.73% to $41.6 million in 2024, then soared by 107.51% to $86.3 million in 2025.
  • Its Non-cash Items was $86.3 million in Q4 2025, compared to $41.6 million in Q4 2024 and $3.4 million in Q4 2023.